MX2022011287A - Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo. - Google Patents
Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo.Info
- Publication number
- MX2022011287A MX2022011287A MX2022011287A MX2022011287A MX2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A MX 2022011287 A MX2022011287 A MX 2022011287A
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- integrin
- addressing
- vivo
- cyclic peptides
- Prior art date
Links
- 102000001189 Cyclic Peptides Human genes 0.000 title abstract 2
- 108010069514 Cyclic Peptides Proteins 0.000 title abstract 2
- 238000001727 in vivo Methods 0.000 title abstract 2
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Radiology & Medical Imaging (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
La invención proporciona conjugados de péptidos cíclicos como ligandos para receptores de la superficie celular, en particular, como ligandos para la integrina avß6. Los conjugados contienen además restos efectores y son adecuados para usarse como agentes terapéuticos, agentes de diagnóstico, agentes de imagenología, residuos objetivo y como herramienta de investigación biomolecular. La invención se relaciona específicamente con el uso de conjugados con restos de señalización o radionúclidos para el direccionamiento de la integrina avß6 in vivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20162699 | 2020-03-12 | ||
| PCT/EP2021/056424 WO2021180969A1 (en) | 2020-03-12 | 2021-03-12 | Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011287A true MX2022011287A (es) | 2022-12-08 |
Family
ID=69810651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011287A MX2022011287A (es) | 2020-03-12 | 2021-03-12 | Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230173113A1 (es) |
| EP (1) | EP4117736A1 (es) |
| JP (1) | JP2023518161A (es) |
| KR (1) | KR20220152322A (es) |
| CN (1) | CN115297893A (es) |
| AU (1) | AU2021233176A1 (es) |
| BR (1) | BR112022016986A2 (es) |
| CA (1) | CA3175061A1 (es) |
| IL (1) | IL296081A (es) |
| MX (1) | MX2022011287A (es) |
| WO (1) | WO2021180969A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2842575T3 (pl) | 2008-03-18 | 2018-02-28 | Seattle Genetics, Inc. | Koniugaty aurystatyny lek łącznik |
| CA2937753A1 (en) | 2014-02-17 | 2015-08-20 | Seattle Genetics, Inc. | Hydrophilic antibody-drug conjugates |
| SI3350222T1 (sl) | 2015-09-18 | 2022-01-31 | Technische Universitaet Muenchen | Ligandi za integrin avbeta6, sinteza in uporaba le-teh |
-
2021
- 2021-03-12 IL IL296081A patent/IL296081A/en unknown
- 2021-03-12 MX MX2022011287A patent/MX2022011287A/es unknown
- 2021-03-12 AU AU2021233176A patent/AU2021233176A1/en active Pending
- 2021-03-12 CN CN202180020982.9A patent/CN115297893A/zh active Pending
- 2021-03-12 US US17/910,728 patent/US20230173113A1/en active Pending
- 2021-03-12 WO PCT/EP2021/056424 patent/WO2021180969A1/en active Search and Examination
- 2021-03-12 EP EP21710520.4A patent/EP4117736A1/en active Pending
- 2021-03-12 KR KR1020227035503A patent/KR20220152322A/ko unknown
- 2021-03-12 JP JP2022549375A patent/JP2023518161A/ja active Pending
- 2021-03-12 CA CA3175061A patent/CA3175061A1/en active Pending
- 2021-03-12 BR BR112022016986A patent/BR112022016986A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023518161A (ja) | 2023-04-28 |
| US20230173113A1 (en) | 2023-06-08 |
| WO2021180969A1 (en) | 2021-09-16 |
| KR20220152322A (ko) | 2022-11-15 |
| CN115297893A (zh) | 2022-11-04 |
| CA3175061A1 (en) | 2021-09-16 |
| AU2021233176A1 (en) | 2022-09-08 |
| EP4117736A1 (en) | 2023-01-18 |
| BR112022016986A2 (pt) | 2022-10-25 |
| IL296081A (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2739613T3 (es) | Péptidos que penetran en las células y sus métodos de preparación y su uso | |
| CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
| ECSP10010467A (es) | Conjugados antagonistas peptídicos análogos a la bombesina | |
| SG158919A1 (en) | Constructs binding to phosphatidylserine and their use in disease treatment | |
| EP2359864A3 (en) | Targeting Vector-Phospholipid Conjugates | |
| HK1130186A1 (en) | Phospholipid analogue for the in vivo diagnosis of cancers | |
| BR112014026730A2 (pt) | conjugados fármaco-ligante de dr5 | |
| EA033456B1 (ru) | Конъюгаты антитело-лекарственное средство, содержащие пептидомиметические линкеры | |
| WO2012112690A3 (en) | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains | |
| WO2010059253A3 (en) | Methods and compositions for localized agent delivery | |
| UA105210C2 (ru) | Противораковая вакцина и ее применение | |
| MXPA04000173A (es) | Compuestos basados en peptidos. | |
| IL176007A0 (en) | Antibodies specific to c35 and pharmaceutical compositions containing the same | |
| UA110473C2 (uk) | Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1 | |
| CL2011003333A1 (es) | El compuesto n-{1s-[2r-(6,6'-difluoro-3'-{4s-hidroxi-1-[2s-(2s-metilamino-propionilamino)-butiril]-pirrolidin-2r-ilmetil}-1h,1'h-[2,2']biindolil-3-ilmetil)-4s-hidroxi-pirrolidin-1-carbonil]-propil}-2s-metilamino-propionamida; composicion farmaceutica; procedimiento de preparacion; compuestos intermediarios; utiles en el tratamiento de un trastorno proliferativo, tal como cancer, entre otros. | |
| WO2009114776A3 (en) | Integrin targeting agents and in-vivo and in-vitro imaging methods using the same | |
| EA201201446A1 (ru) | Пептидные производные, их получение и применение | |
| NZ700296A (en) | Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites | |
| MX2008008185A (es) | Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer. | |
| MX2023002330A (es) | Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos. | |
| WO2009076388A3 (en) | Targeting vector-phospholipid conjugates | |
| GB201103696D0 (en) | Technetium labelled peptides | |
| MX2022011287A (es) | Peptidos ciclicos y sus conjugados para el direccionamiento de la integrina alfa-v-beta-6 in vivo. | |
| ATE536368T1 (de) | Konjugate von zytotoxischen verbindungen mit peptiden |